TNF and cancer: While the optimal DC phenotype for cancer immunotherapy remains controversial, it is increasingly recognized that incorporation of IL-12p70-producing DC1 – which subsequently polarize naïve CD4+ T-cells toward a IFN-γ and TNF-α-secreting T-helper type 1 (Th1) phenotype (20) – appears advantageous.